In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
The inaugural meeting of the EUHTF in January 2024 marked a significant milestone in strengthening the EU's preparedness and response capacity to face public health emergencies.
The purpose of the Audit Committee is to assist the Management Board in fulfilling its oversight responsibilities for the financial reporting process, the system of internal control and the audit process.
In a joint report released today, ECDC and EFSA outline the contributing drivers for influenza A(H5N1) viruses to acquire the ability to spread efficiently among humans, thereby increasing their pandemic potential.
Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds.
MediPIET/EPIET and EUPHEM fellows participated in a two-day optional module organised by ECDC, aimed at refining their proficiency in qualitative research methodologies.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.